Review article

Parkin-linked Parkinson’s disease: From clinical insights to pathogenic mechanisms and novel therapeutic approaches

Kobi Wasner a, Anne Grünewald a, b, Christine Klein b, * 

a Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg 
b Institute of Neurogenetics, University of Lübeck, Lübeck, Germany

ARTICLE INFO

Article history: 
Received 1 August 2020 
Accepted 4 August 2020 
Available online xxx

Keywords: 
Parkin 
Parkinson's disease 
Mitochondria 
Inflammation 
Gene-specific therapy 
Clinical trial

ABSTRACT

With over 7 million patients worldwide, Parkinson’s disease (PD) is becoming more prevalent as life span and industrialization increase. While the majority of cases are sporadic and present in individuals over 65, inherited mutations in Parkin can manifest in individuals as young as teenagers. The involvement of Parkin in neurodegeneration has been widely investigated and its role in mitophagy is undeniable. In the recent years, however, additional functions of the protein are beginning to come to light, which in turn may influence the way patients harboring Parkin mutations are treated. In the present article, we discuss the clinical and genetic aspects of Parkin-linked PD. For this purpose, we consulted the MDSGene database, which comprises the literature of more than 1000 patients with Parkin mutations. In addition, we provide insight into Parkin’s multifaceted role in mitochondrial clearance and maintenance. Finally, we discuss treatment strategies such as brain stimulation, small molecule drugs and dopaminergic cell replacement that could be tailored to improve the clinical phenotypes in Parkin-linked PD.

© 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Contents

1. Introduction .......................................................................................................................... 00
2. Parkin-linked PD: clinical aspects ....................................................................................... 00 
   2.1. Parkin-linked PD: genetic aspects .................................................................................. 00 
   2.2. Protein structure of Parkin ......................................................................................... 00 
3. Mitochondrial involvement in Parkinson’s disease .............................................................. 00 
   3.1. Parkin and mitophagy .................................................................................................. 00 
   3.2. Parkin and mitochondrial biogenesis .......................................................................... 00 
4. Inflammation ...................................................................................................................... 00 
5. Treatment ........................................................................................................................... 00 
Acknowledgements .............................................................................................................. 00 
References ............................................................................................................................... 00

1. Introduction

While Parkinson’s disease (PD) was first systematically described by the British physician James Parkinson in 1817, it took almost two centuries until the first recessively inherited form of PD was discovered by Kitada and colleagues in Japan in 1998 (Kitada et al., 1998). In his work entitled “An Essay on the Shaking Palsy”, James Parkinson characterized the symptoms of six individuals – including some patients and individuals on the street - with what he named paralysis agitans – a malady resulting in, “involuntary tremulous motion, with lessened muscular power, in parts not in action and even when supported” (Parkinson, 2002). This condition was later named after James Parkinson and, in reference to the term ‘Parkinson’s disease’, Kitada et al. chose to name their newly identified gene ‘Parkin’. Although the most striking clinical difference between Parkin mutation carriers and classical PD was the very early, juvenile age at onset (AAO) in the former, the clinical presentation caused by Parkin mutations was compatible with a diagnosis of PD, albeit characterized by a strong susceptibility to dopa-induced dyskinesia and motor fluctuations. Further
extending the close phenotypic link of Parkinson-linked PD and ‘idiopathic’ PD, i.e. PD of unknown origin and typically late AAO, Parkinson mutations were soon identified also in a family with late-onset tremor-dominant PD (Klein et al., 2000).

The exact frequency of Parkinson mutations is currently unknown, which is especially true for the most common, late-onset patient population where systematic mutational screens are lacking. However, Parkinson mutations are overall rare and, even in the younger AAO groups (<50 years) account for ~2.6% of the cases only (Tan et al., 2019). Mutation frequency increases with decreasing AAO and is highest in the juvenile group (AAO < 20 years) where biallelic Parkinson mutations are found in up to 77% of the patients (Lucking et al., 2000). Given the ‘PD Pandemic’ with PD being the fastest growing neurological disease with a current estimated global number of ~7 million PD patients (Dorsey and Bloem, 2018), one may expect a total of 35,000–70,000 Parkinson cases worldwide when assuming an estimated fraction of Parkinson mutation carriers across all AAO groups of 0.5–1%.

2. Parkinson-linked PD: clinical aspects

The Movement Disorder Society Genetic mutation database (MDSGene; www.mdsgene.org) provides a comprehensive online resource linking reported genetic mutations with movement disorder phenotypes as well as with demographic and other clinical information including PARK-Parkin (Kasten et al., 2018). MDSGene currently lists 1000 biallelic Parkinson mutation carriers (44% female) with PD and a median AAO of 31 years (25th/75th percentile: 23/39 years; range: 3–73 years). The most common presenting sign is tremor, followed by bradykinesia and dystonia. Indeed, across all listed patients, dystonia is the most common clinical feature after the cardinal PD signs and is present in 65% of those with available information. Under scoring the importance of dystonia as a prominent feature of Parkinson-linked PD especially in the very early-onset patients, the percentage of patients with dystonia rises to 85% in those with a juvenile AAO, i.e. with an onset of PD at 20 years or younger. As already mentioned in the original description of the Parkinson gene (Kitada et al., 1998), dyskinesia is a common finding in Parkinson mutation carriers and found in 78% of all patients with available information on this feature and in even 90% of those with a juvenile AAO. Likewise, motor fluctuations occur at high frequency (87%), and are only slightly more common in the juvenile onset group (91%). Non-motor signs do occur in Parkinson mutation carriers, however, reporting has been inconsistent and data missingness is high.

As information on the presence or absence of non-motor signs and symptoms has been provided for 100 Parkinson mutation carriers (10%) or fewer, 90% data missingness does not allow for meaningful conclusions on the frequency of the following features: autonomic signs or symptoms, sleep benefit, depression, anxiety, and psychiatric signs and symptoms. By contrast, previous meta-analyses of published PD patients with Parkinson mutations indicated that dementia is very rare, affecting less than 3% of cases (Grunewald et al., 2013; Kasten et al., 2018). The largest fraction of Parkinson mutation carriers is of Asian origin (37% overall; 44% in the juvenile AAO group), including 10% from Japan, followed by White European (35%).

2.1. Parkinson-linked PD: genetic aspects

To review the mutational spectrum of Parkinson, we also consulted MDSGene and our in-house database on published heterozygous Parkinson mutation carriers. To date, 200 different mutations have been published. These include 18 variations in introns, 13 nonsense mutations, 69 missense mutations, 29 small insertions or deletions, and 71 exon rearrangements (including 42 deletions and 26 multiplications). Out of 1155 mutation-positive index patients, 778 (67%) carried at least one exon rearrangement with exon 3 deletions being the most common and affecting 120 (10%) index patients (on one or two mutant alleles).

When assessing the impact of different mutation types on the AAO, we did not observe any significant group differences across index patients with homozygous mutations (variants in introns: AAO [SD], 23.8 [10.1] years, n = 4; nonsense mutations: 31.4 [8.1] years, n = 8; missense mutations: 35.0 [17.5] years, n = 35; small insertions/deletions: 31.0 [11.3] years, n = 75; exon rearrangements: 32.9 [11.5] years, n = 200). The same observation was made when focusing exclusively on index patients with heterozygous mutations (variants in introns: n/a; nonsense mutations: AAO [SD], 30.2 [14.3] years, n = 5; missense mutations: 42.3 [13.3] years, n = 125; small insertions/deletions: 35.6 [12.3] years, n = 27; exon rearrangements: AAO [SD], 40.9 [13.8] years, n = 238).

By contrast, comparing the mean AAO of all index patients with biallelic (AAO [SD], 31.3 [12.0], n = 663) vs. those with heterozygous mutations (40.7 [13.7] years, n = 409), we determined a difference of about ten years (p < 0.0001). With an AAO in the forties, Parkinson heterozygotes suffer from PD about ten years earlier than idiopathic patients who typically develop first signs in their 6th decade of life (Grunewald et al., 2013). To obtain an even clearer picture of the influence of heterozygous Parkinson mutations on the onset of PD, we repeated the aforementioned analysis for exon 3 deletion carriers only. Interestingly, in this homogenous (albeit small) subset, the AAO was as low in heterozygotes (AAO [SD], 33.1 [6.3], n = 10) as in homozygotes (32.6 [10.2], n = 42). Of note, for all AAO analyses, individuals with known digenic inheritance of PD-associated mutations were excluded.

2.2. Protein structure of Parkinson

Parkinson is a 465-residue protein involved in the ubiquitin-proteasome system: a process which mediates the targeting of proteins for degradation. As an E3 ubiquitin ligase, Parkinson recruits an E2 ubiquitin conjugating enzyme to facilitate the transfer of a ubiquitin substrate onto its target protein. The addition of ubiquitin onto a protein can produce a variety of effects including degradation via the proteasome, alteration of its cellular location, or promote or prevent protein–protein interactions (Seirafi et al., 2015).

Parkinson belongs to the RING-between-RING family of E3 ligases, which generally comprises of two RING finger domains and an in-between-RING region. RING1 serves as the binding site for an E2 ubiquitin conjugating enzyme, while RING2 contains an active site cysteine residue, which accepts and cleaves ubiquitin from the E2 enzyme and transfers it onto its substrates. A ubiquitin-like domain is also present at the N-terminus of Parkinson and plays a role in substrate recognition.

An ample amount of studies have found that Parkinson is largely a cytosolic protein mediating ubiquitination in the cytosol. However, several studies have also shown small pools of Parkinson localized to mitochondria (Kuroda et al., 2006; Narendra et al., 2008; Rothfuss et al., 2009).

3. Mitochondrial involvement in Parkinson’s disease

The foundation of PD research was forever changed in the late 20th century in California, United States. In the summer of 1982, emergency rooms in San Francisco were abruptly met with peculiarly “frozen” patients: young women and men who were unable to move or speak, yet were conscious. Neurologist James William Langston recognized these symptoms as advanced PD and adminis-
tered the only known effective treatment – L-DOPA – and “unfroze” the patients.

The patients were found to be drug users who ingested “China White” – a synthetic opioid analgesic produced by drug dealers. Analysis of the drug determined its chemical name: 1-methyl-4-phenyl-1,2,3,6-tetrahydro-3.1-terted pyridine (MPTP). Unbeknownst to them, this toxic compound was the perfect inhibitor of mitochondrial respiration.

3.1. Parkin and mitophagy

Damaged mitochondria are quickly degraded and replaced in the healthy brain. One of the most prominent and studied functions of Parkin is its role in mitophagy – the selective degradation of malfunctioning mitochondria by autophagy. Mitochondrial damage results in the depolarization of the outer mitochondrial membrane (OMM), thereby preventing PINK1 import through the OMM transmembrane protein complexes (Narendra et al., 2008). PINK1 subsequently accumulates along the OMM and begins to phosphorylate its targets, including ubiquitin and Parkin at serine 65 (Shiba-Fukushima et al., 2012). Phosphorylation at these sites activates and recruits Parkin to the OMM where Parkin subsequently begins to transfer ubiquitin onto its targets including mitofusins, VDACs and BAK (Fig. 1) (Bernardini et al., 2019; Geisler et al., 2010; Kane et al., 2014; Sarraf et al., 2013). Ubiquitin chain linkages on K48 primes degradation of the proteins by the proteasome, while K63 ubiquitination is recognized by autophagy adaptors, which eventually form the autophagosome, leading to its destruction by lysosomes.

Mitochondria are highly dynamic organelles, whereby a balance of degradation and biogenesis is mediated by morphological changes through fission and fusion (Deng et al., 2008). Mitofusin 1 and 2 (MFN1/2), which are downstream targets of Parkin, facilitate the fusion of the OMM, while Dynamin-related protein 1 (Drp1) regulates the fission of the inner mitochondrial membrane (IMM). Animal models lacking Parkin show striking mitochondrial morphological phenotypes including swelling, herniation and broken cristae (Deng et al., 2008).

Mitophagy is a process performed by the cell in order to combat dysfunction and as a resort to prevent cell death. Once past a certain threshold and committing to a cell death fate, intrinsic apoptosis is mediated by the permeabilization of mitochondrial membranes and release of pro-apoptotic factors such as cytochrome C. Perforation of the mitochondrial membranes is executed by BAK and BAX, which are recruited to the OMM and form oligomers, which puncture the membranes (Fig. 1). Parkin reduces BAX localization to the OMM through an indirect interaction and also directly ubiquitinates BAX, preventing its development into oligomers and subsequent destruction of the OMM and release of cytochrome C (Bernardini et al., 2019). Thus, Parkin-mediated mitophagy also serves to prevent apoptosis.

During oxidative stress and mitophagy, mitochondria release signals to other organelles in response to a variety of stimuli. Mitochondrial-derived vesicles (MDVs) are filled with oxidized cargo that bud off mitochondria (independently of mitochondrial fission). Parkin colocalizes with MDVs and stimulates their formation in response to ROS (Mclelland et al., 2014).

Recent evidence revealed Parkin’s many functions other than governing mitophagy; Parkin ubiquitinates hundreds of targets, which play other roles in mitochondrial pathways, it contains the structural architecture common in several transcription factors and associates with the mitochondrial genome (Alves da Costa et al., 2018).

3.2. Parkin and mitochondrial biogenesis

 Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α) is a transcriptional coactivator known as the master regulator of mitochondrial biogenesis, where it transcribes a multitude of downstream target genes responsible for mitochondrial maintenance and respiration including nuclear respiratory factors (NRFs) and estrogen-related receptors (ERRs). Overexpression of PGC-1α leads to an increase of these targets, mitochondrial-encoded proteins and mitochondrial DNA (mtDNA) copy number (Zheng et al., 2017).

One of Parkin’s targets for ubiquitination, Parkin interacting substrate (PARIS), is a transcriptional repressor of PGC-1α (Fig. 1). PARIS is ubiquitously expressed throughout the body and heterogeneously expressed throughout the brain, where it is localized to neurons, including midbrain dopaminergic neurons of the substantia nigra (SN) pars compacta. Consequently, PARIS protein accumulates in the brain of patients with autosomal recessive juvenile PD. Mutations to Parkin result in the accumulation of PARIS and successive inhibition of the transcription of PGC-1α and its downstream targets (Shin et al., 2011; Zheng et al., 2017). Thus, Parkin is not only responsible for the degradation of damaged mitochondria, but also plays a role in the mitochondrial biogenesis pathway.

The generation of new mitochondria requires the replication and transcription of the mitochondrial genome, which are mainly regulated by nuclear-encoded proteins. PGC-1α targets NRF1 and NRF2 – transcription factors, which activate the expression of molecules maintaining mtDNA (Gugneja et al., 1996). NRF-1 and NRF-2 transcribe TFAM and TFB2M, two molecules required for the initiation of transcription and replication of the mitochondrial genome.

NRF-1 abundance has been shown to be reduced in cells which lack Parkin (Shin et al., 2011; Stevens et al., 2015), and interestingly, NRF-1 was shown to contain binding sites in both Parkin and PINK1 promoter regions in silico, in vitro and in vivo (Suliman et al., 2017). This was supported by overexpression of NRF-1, which lead to an increase in Parkin and PINK1 gene and protein expression, while silencing of NRF-1 lead to Parkin and PINK1 downregulation. Moreover, Parkin mutations and consequential downregulation of PGC-1α causes loss of NRF-1 and TFAM.

TFAM is crucial for the maintenance of the mitochondrial genome. Its functions include the mtDNA copy number, initiation of mtDNA transcription, participation in mtDNA replication and compaction of the mitochondrial genome into protein-rich structures termed nucleoids. Upon activation by regulatory proteins, such as NRF-1, TFAM translocates from the cytosol to the nucleoid and regulates mitochondrial transcription (Fig. 1). The mitochondrial genome is located in the mitochondrial matrix and in close proximity to the electron transport chain (ETC) protein complexes. In the process of producing ATP for the cell, toxic by-products, like reactive oxygen species, are also generated and can harm mtDNA molecules (Mecocci et al., 1993). Moreover, deletions in mtDNA accumulate with normal aging in the SN and occur more frequently in PD patients than in age-matched controls (Bender et al., 2006; Kraysberg et al., 2006). mtDNA depletion and downregulation of TFAM and mtDNA transcription have also been found in post-mortem tissue of PD patients (Grunewald et al., 2016).

Parkin overexpression increases mtDNA-encoded RNA and proteins, which are transcribed by TFAM. Thus, in 2006, Kuroda and colleagues hypothesized that Parkin is associated with TFAM. Using co-immunoprecipitation in COS-1 cells, results showed that Parkin indeed interacts directly with TFAM. Mobility shift assays showed a shift in mtDNA, when TFAM was present, suggesting that Parkin can associate with mtDNA indirectly via TFAM. These findings were reproduced and confirmed on an endogenous level in SH-
SY5Y cells; ChIP on chip analyses showed that Parkin associates with several mitochondrial genomic sequences including ATPase 6, COXII, ND1, ND2 and D-LOOP. Moreover, Parkin and TFAM co-associate at several of the same mtDNA sequences in post-mitotic neurons and in vivo, and Parkin was shown to protect mitochondrial genome integrity (Rothfuss et al., 2009). By contrast, Parkin’s putative role in mtDNA maintenance has not yet been investigated in patient-derived neuronal models with Parkin mutations.

In induced pluripotent stem cell (iPSC)-derived neuronal progenitor cells from Parkin-mutant PD patients and age-matched controls (Fig. 2A), we assessed the abundance of somatic major arc deletions and did not detect differences between the two groups (Fig. 2B). By contrast, when quantifying the presence of 7S DNA, which binds in the D-loop during mtDNA transcription and replication, we observed reduced levels in patient cells (Fig. 2C). This result fur-
ther implicates impaired mtDNA homeostasis in the pathogenesis of Parkin-linked PD.

While mouse models have unraveled an extraordinary amount of biological mechanisms regarding PD, Parkin-knockout (KO) mice do not display signs of nigrostriatal neurodegeneration or any significant motor phenotypes typical of PD. As variations in the DNA polymerase γ (POLG) gene have been identified as risk factors in PD, Pickrell and colleagues hypothesized that lack of Parkin in mice with increased mutagenic stress may provide a better model to study Parkin-related PD. The mutator-Parkin-KO mouse combines a mutation to the only mtDNA proofreading factor POLG and Parkin KO, subjecting the mice to both mutagenic and loss of Parkin. These mice exhibit PD symptoms and the selective loss of dopaminergic neurons of the SN. In these mice, mtDNA depletion and mutation rate was significantly increased compared to WT mice. Moreover, loss of Parkin expression during mutagenic stress increased the predicted pathogenicity of the incurred mutations (Pickrell et al., 2015).

4. Inflammation

In the last decade, an exciting and novel theme has emerged in the pathophysiology of age and aging-related disorders: the role of mitochondria as a trigger for the immune system. Once independent bacteria, mitochondria contain their own DNA located within the mitochondrial matrix. If found outside the matrix, such as the cytosol or extracellular space, mtDNA can be perceived as foreign and potentially toxic. Such molecules released from their natural compartments as a result of cellular stress and/or injury are termed damage-associated molecular patterns (DAMPs) and can initiate a non-infectious inflammatory response, whereby cytosolic and/or extracellular pattern recognition receptors (PRRs) recognize and activate inflammatory pathways to prompt innate immunity (Roh and Sohn, 2018).

TFAM is the major protein comprising nucleoids, and TFAM downregulation has been shown in post mortem idiopathic PD brains and correlates with a loss of 75 DNA-associated mtDNA transcription and depletion (Grunewald et al., 2016). In TFAM-knock down mouse embryonic fibroblasts, loss of TFAM leads to mtDNA escape into the cytoplasm prompting its “foreign” recognition and subsequent activation of the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) innate immune response, thereby resulting in proinflammatory cytokine signaling (Fig. 1) (West et al., 2015).

As mitophagy selectively degrades malfunctioning mitochondria, it is plausible that mitophagy may reduce the expulsion of DAMPs from mitochondria. Compared to wild type mice, Parkin-deficient mice presented with significantly higher concentrations of IL-6, IFNβ1, IL-12 p70, IL-13, CXCL1, CCL2 and CCL4 in serum, which was dependent on cGas-STING activation. Human serum from biallelic Parkin-mutation carriers also showed significantly higher levels of IL-6, IL-1β, and CCL4 compared to healthy controls, suggesting that lack of Parkin results in an increase in cytokines preceding symptomatic neurodegeneration (Sliter et al., 2018). IFNβ1, a type 1 interferon, is produced upon STING activation. In similar fashion, in our recent biomarker study, serum from Parkin-mutation carriers showed higher levels of cell-free circulating mtDNA and IL-6 levels compared to both idiopathic PD patients and healthy controls. Moreover, IL-6 levels correlated with disease duration in Parkin mutation carriers (Borsche et al., 2020).

5. Treatment

The overwhelming majority of Parkin mutation carriers respond favorably to Levodopa treatment (>98 %). Of those with reported information, 93 % respond well to Levodopa and only a small minority shows a moderate (4 %) or minimal (3 %) response, respectively (www.mdsgene.org). Although prospective studies are still lacking, it appears that deep brain stimulation is as effective in Parkin mutation carriers as in idiopathic PD patients (de Oliveira et al., 2019; Kim et al., 2014; Rizzone et al., 2018).

More recently, therapeutic approaches are being explored that target specific Parkin mutation-induced (dys-)function including mitochondria. A small molecule activator of mitophagy, either activating Parkin or PINK1 directly or inhibiting Parkin’s counterpart, the ubiquitin-specific protease USP20, are in preclinical development (Miller and Muqit, 2019). It has also been argued that Parkin-PD patients would be particularly well-suited candidates for dopaminergic cell replacement therapies based on the frequent confinement of their neurodegeneration to the nigrostriatal pathway and on their overall younger age and rarer occurrence of comorbidities (Kunath et al., 2019). In this context, it is exciting to note that patient-derived midbrain dopaminergic progenitor cells, differentiatated in vitro from autologous iPSCs, were successfully implanted in a patient with idiopathic PD. The cells were demonstrated to have the phenotypic properties of SN pars compacta neurons and were implanted into both putamina without the need for immunosuppression. Positron-emission tomography with the use of fluorine-18-L-dihydroxyphenylalanine indicated graft survival which was paralleled by stabilization or even improvement of PD signs and symptoms at 18–24 months after implantation (Schweitzer et al., 2020). It remains to be explored whether implantation of (mutation-corrected) autologous iPSC-derived neurons would be an equally viable therapeutic strategy for Parkin-linked PD.

Finally, the detection of elevated cytokine levels in the serum of patients with Parkin mutations suggests that anti-inflammatory treatments could be considered to modulate the progression of PD in these cases (Borsche et al., 2020).

Acknowledgements

CK receives funding within the framework of SysMedPD (European Union’s Horizon 2020 research and innovation program). CK and AG are funded by the German Research Foundation (FOR2488, GR 3731/5-1). AG and KW are supported by the Luxembourg National Research Fund (ATTRACT career development grant, FNR9631103; INTERR grant, FNR11250962).

References


